Hot Features
プレミアム
Prelude Therapeutics Inc (PRLD)
NASDAQ
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in...
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -4.7619047619 | 2.1 | 2.16 | 1.86 | 168838 | 2.00430217 | CS |
| 4 | -2.9 | -59.1836734694 | 4.9 | 5.53 | 1.86 | 439999 | 2.73110439 | CS |
| 12 | -2.6 | -56.5217391304 | 4.6 | 6.8 | 1.86 | 293462 | 4.06366699 | CS |
| 26 | -2.72 | -57.6271186441 | 4.72 | 6.8 | 1.86 | 166320 | 4.05096919 | CS |
| 52 | -0.82 | -29.0780141844 | 2.82 | 6.8 | 1.66 | 154487 | 3.64529011 | CS |
| 156 | -22.6 | -91.8699186992 | 24.6 | 24.6 | 1.66 | 177689 | 7.80555748 | CS |
| 260 | -23.76 | -92.2360248447 | 25.76 | 95.375 | 1.66 | 191143 | 19.01249551 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
